Abstract
The discoveries of the pluripotent role of glycogen synthase kinase-3 (GSK-3) are pointing to GSK-3 as a potential target for therapy of neurodegenerative disorders and type 2 diabetes. GSK-3 is a constitutively active protein kinase that is inhibited in response to various extracellular signals. Lithium has been found to be an important inhibitor of GSK-3 activity and its use as a laboratory tool has contributed to the understanding of the role of GSK-3. Fluoride has been often used in study designs on GSK-3 as the inhibitor of protein phosphatases. Potential interactions of fluoride with the observed lithium effects are discussed.
Keywords: Glycogen synthase kinase-3 (GSK-3), lithium, fluoride, aluminofluoride complexes, protein phosphatase -1
Current Enzyme Inhibition
Title: Potential Lithium and Fluoride Interactions in Studies of Glycogen Synthase Kinase-3
Volume: 4 Issue: 3
Author(s): Anna Strunecka and Jiri Patocka
Affiliation:
Keywords: Glycogen synthase kinase-3 (GSK-3), lithium, fluoride, aluminofluoride complexes, protein phosphatase -1
Abstract: The discoveries of the pluripotent role of glycogen synthase kinase-3 (GSK-3) are pointing to GSK-3 as a potential target for therapy of neurodegenerative disorders and type 2 diabetes. GSK-3 is a constitutively active protein kinase that is inhibited in response to various extracellular signals. Lithium has been found to be an important inhibitor of GSK-3 activity and its use as a laboratory tool has contributed to the understanding of the role of GSK-3. Fluoride has been often used in study designs on GSK-3 as the inhibitor of protein phosphatases. Potential interactions of fluoride with the observed lithium effects are discussed.
Export Options
About this article
Cite this article as:
Strunecka Anna and Patocka Jiri, Potential Lithium and Fluoride Interactions in Studies of Glycogen Synthase Kinase-3, Current Enzyme Inhibition 2008; 4 (3) . https://dx.doi.org/10.2174/157340808785909394
DOI https://dx.doi.org/10.2174/157340808785909394 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Determination of Lipoic Acid in the form of 2-S-pyridinium Derivative by High-performance Liquid Chromatography with Ultraviolet Detection
Current Analytical Chemistry Regulation of Neuronal Cell Death and Neurodegeneration by Members of the Bcl-2 Family: Therapeutic Implications
Current Drug Targets - CNS & Neurological Disorders PPARs in Neurodegenerative and Neuroinflammatory Pathways
Current Alzheimer Research Programmed Cell Death Mechanisms in Neurological Disease
Current Molecular Medicine Cardiovascular Toxicity from the Perspective of Oxidative Stress, Electron Transfer, and Prevention by Antioxidants
Current Vascular Pharmacology Plant Troponoids: Chemistry, Biological Activity, and Biosynthesis
Current Medicinal Chemistry Serotonin 1A Receptors on Astrocytes as a Potential Target for the Treatment of Parkinson’s Disease
Current Medicinal Chemistry IDO and Clinical Conditions Associated with Depressive Symptoms
Current Drug Metabolism Effects of Erythropoietin on Brain Function
Current Pharmaceutical Biotechnology Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease
Current Alzheimer Research Towards Retinoid Therapy for Alzheimers Disease
Current Alzheimer Research Nanomedicine against Alzheimer’s and Parkinson’s Disease
Current Pharmaceutical Design The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review
Current Neuropharmacology Central Nervous System-Related
Current Bioactive Compounds Nanoparticles, Neurotoxicity and Neurodegenerative Diseases
Current Drug Metabolism Pentameric models as alternative molecular targets for the design of new antiaggregant agents
Current Protein & Peptide Science Old Friends in New Constellations - the Hematopoetic Growth Factors G-CSF, GMCSF, and EPO for the Treatment of Neurological Diseases
Current Medicinal Chemistry Emerging RNA-based Drugs: siRNAs, microRNAs and Derivates
Central Nervous System Agents in Medicinal Chemistry S-Nitrosylation and Attenuation of Excessive Calcium Flux by Pentacycloundecane Derivatives
Medicinal Chemistry Progress of Computer-Aided Drug Design (CADD) of Proteasome Inhibitors
Current Topics in Medicinal Chemistry